Rachel Klemovitch, Assistant Editor09.07.23
Women’s health medical device company, Caldera Medical, announced the completed acquisition of Atlantic Therapeutics, an Ireland based provider of medical devices and related software, specializing in of non-invasive pelvic floor strengthening and nerve stimulating devices for women.
“We are thrilled to acquire Atlantic Therapeutics and scale the rapidly growing Innovo products worldwide. This acquisition aligns perfectly with our mission and allows us to offer an even more comprehensive suite of solutions to healthcare providers and patients alike,” said Caldera Medical CEO Byron Merade.
Caldera Medical develops and markets products in its European headquarters and innovation center in Galway, Ireland. The company’s products are designed for the treatment of Stress Urinary Incontinence, Pelvic Organ Prolapse and Fibroids. This acquisition expands the company’s portfolio adding Atlantic Therapeutic’s commercial leading non-invasive FDA cleared Innovo products, a first-line therapy for women with stress urinary incontinence.
Atlantic Therapeutics CEO Susan Trent told the press, “since its formation, the team at Atlantic Therapeutics has demonstrated the huge potential for Innovo. This unique technology with robust clinical data is ideally placed to serve millions of women worldwide who suffer from the daily stress of SUI. Caldera Medical’s ability to maximize this potential is the perfect next step. I am delighted that we will see Innovo thrive within Caldera Medical, and we want to thank Byron and the team for their dedication to women’s health.”
“We are thrilled to acquire Atlantic Therapeutics and scale the rapidly growing Innovo products worldwide. This acquisition aligns perfectly with our mission and allows us to offer an even more comprehensive suite of solutions to healthcare providers and patients alike,” said Caldera Medical CEO Byron Merade.
Caldera Medical develops and markets products in its European headquarters and innovation center in Galway, Ireland. The company’s products are designed for the treatment of Stress Urinary Incontinence, Pelvic Organ Prolapse and Fibroids. This acquisition expands the company’s portfolio adding Atlantic Therapeutic’s commercial leading non-invasive FDA cleared Innovo products, a first-line therapy for women with stress urinary incontinence.
Atlantic Therapeutics CEO Susan Trent told the press, “since its formation, the team at Atlantic Therapeutics has demonstrated the huge potential for Innovo. This unique technology with robust clinical data is ideally placed to serve millions of women worldwide who suffer from the daily stress of SUI. Caldera Medical’s ability to maximize this potential is the perfect next step. I am delighted that we will see Innovo thrive within Caldera Medical, and we want to thank Byron and the team for their dedication to women’s health.”